Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs ACTRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
Migraine pain relief,Headache,Muscle aches,Menstrual cramps,Arthritis,Reduction of risk of myocardial infarction (low-dose)
Mild to moderate pain,Fever
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by hepatic esterases to salicylate; conjugation with glycine (salicyluric acid) and glucuronic acid (salicyl phenolic glucuronide) mainly in the liver; also metabolized by cytochrome P450 (CYP) enzymes (CYP2C9) to a lesser extent.
Primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1, SULT1A3), and oxidation (CYP2E1, CYP3A4) to form the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and p H-dependent: alkaline urine increases clearance.
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
80-90% bound to serum albumin, primarily binding site I (warfarin site). Binding is saturable and decreases at high concentrations, increasing free fraction and toxicity risk.
>99% bound to albumin.
0.15-0.2 L/kg for aspirin; for salicylate 0.1-0.2 L/kg. Low Vd reflects limited extravascular distribution; does not extensively penetrate brain except at high doses (therapeutic for migraine likely CNS penetration via passive diffusion).
0.1-0.2 L/kg; indicates limited extravascular distribution.
Oral immediate-release aspirin: 50-75% (due to first-pass hydrolysis in GI mucosa and liver). Enteric-coated: reduced and delayed absorption. Rectal: 20-50% (variable). For BAYER EXTRA STRENGTH ASPIRIN (500 mg), ~60% bioavailability.
Oral: 70-90% (first-pass metabolism minimal); IV: 100%.
GFR 10-50 m L/min: avoid or reduce dose to 500 mg every 6 hours; GFR <10 m L/min: contraindicated.
GFR <30 m L/min: Avoid use. GFR 30-50 m L/min: Reduce dose to 50% of normal, maximum 600 mg/day.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% or extend interval to 8 hours; Class C: contraindicated.
Child-Pugh Class B: Reduce dose by 50%; maximum 600 mg/day. Child-Pugh Class C: Contraindicated.
Weight <40 kg: 10-15 mg/kg orally every 4-6 hours, maximum 60 mg/kg/day; Weight ≥40 kg: adult dosing.
Children ≥12 years: 400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Children <12 years: Not recommended.
Start at lowest effective dose (500 mg every 6-8 hours); monitor renal function and bleeding risk.
Initiate at 200 mg every 6-8 hours; maximum 600 mg/day due to increased risk of gastrointestinal bleeding and renal impairment.
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most cases involve use of acetaminophen at doses exceeding 4000 mg per day, often involving more than one acetaminophen-containing product.
Increased risk of gastrointestinal bleeding, ulcers, and perforation; hypersensitivity reactions including anaphylaxis; increased bleeding risk; severe hepatic injury; caution in patients with asthma, G6PD deficiency, renal impairment, or history of peptic ulcer disease.
Hepatotoxicity: risk increased with chronic alcohol use, liver disease, or use of other acetaminophen-containing products. Avoid exceeding 4000 mg/day. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis. Hypersensitivity reactions: anaphylaxis.
Hypersensitivity to aspirin or NSAIDs; active peptic ulcer disease; severe hepatic or renal impairment; bleeding disorders; patients with viral infections (children/teenagers) due to Reye's syndrome risk; third trimester of pregnancy.
Severe hepatic impairment or active liver disease. Known hypersensitivity to acetaminophen or any component of the formulation.
High-fat meals may delay absorption and reduce efficacy. Avoid alcohol to minimize GI bleeding risk. No significant food interactions beyond general GI irritation, but taking with food may improve tolerance.
Avoid alcohol; may increase risk of GI bleeding. No specific food restrictions, but taking with food can reduce gastrointestinal irritation. Maintain adequate hydration to prevent renal impairment.
First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: Avoid due to potential effects on fetal renal function and premature closure of ductus arteriosus, though risk is lower than third trimester. Third trimester: Contraindicated. Use in third trimester increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage in the fetus; may prolong gestation and labor.
First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios with prolonged use. Avoid after 30 weeks gestation.
Aspirin (acetylsalicylic acid) is excreted into breast milk in low concentrations. Milk-to-plasma ratio (M/P) is approximately 0.03-0.11 for salicylate. No adverse effects in breastfeeding infants have been reported with occasional low doses. However, regular high-dose use may lead to accumulation and potential toxicity in the infant (e.g., Reye's syndrome). Avoid use during breastfeeding; if needed, use lowest effective dose and monitor infant for bruising, bleeding, or metabolic acidosis.
Excreted in breast milk; M/P ratio 0.15. Low oral bioavailability to infant; considered compatible with breastfeeding. Monitor infant for sedation or feeding problems.
Aspirin pharmacokinetics in pregnancy: Increased renal clearance and plasma volume may lower salicylate concentrations. However, due to teratogenic risks, routine aspirin use is not recommended. For specific indications (e.g., preeclampsia prevention, antiphospholipid syndrome), low-dose aspirin (81 mg/day) is used without dose adjustment. For high-dose or anti-inflammatory doses (e.g., 650 mg every 4-6 hours), avoid entirely in pregnancy, especially in third trimester.
Dose adjustment not typically required; however, due to increased renal clearance and volume of distribution in pregnancy, higher doses may be needed to achieve therapeutic effect. Use lowest effective dose for shortest duration.
For migraine pain, aspirin 500-1000 mg (equivalent to 2-4 tablets of Bayer Extra Strength) is recommended at onset. Note that aspirin is contraindicated in patients with a history of nasal polyps, angioedema, or bronchospasm with NSAIDs. Monitor for tinnitus or hearing loss as signs of salicylate toxicity. Avoid use within 48 hours of alcohol cessation therapy due to GI irritation.
ACTRON (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) for short-term management of moderate to severe acute pain, typically not exceeding 5 days due to risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with active peptic ulcer disease, bleeding diathesis, or advanced renal disease. Monitor renal function and signs of bleeding. Use lowest effective dose for shortest duration. May cause bronchospasm in aspirin-sensitive asthma.
Take this medication at the first sign of migraine pain for best results.,Do not exceed 8 tablets (4000 mg aspirin) in 24 hours.,Avoid alcohol while taking aspirin to reduce risk of stomach bleeding.,Do not use if you have a history of stomach ulcers, bleeding disorders, or asthma triggered by aspirin.,Consult a doctor if your migraine does not improve after 1-2 doses or if you have severe symptoms.,Keep out of reach of children; Reye's syndrome warning if given to children or teenagers with viral illness.
Take with food or milk to reduce stomach upset.,Do not take for more than 5 days as prescribed; longer use increases risk of serious side effects.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Report any signs of bleeding (e.g., black stools, vomiting blood), unusual bruising, or decreased urination.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting your doctor.,Inform your doctor about all medications, especially blood thinners (e.g., warfarin) and diuretics.,If you have asthma, be aware of potential bronchospasm; seek immediate help if you have breathing trouble.,Not recommended during pregnancy, especially in the third trimester.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs ACTRON, answered by our medical review team.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is a NSAID / Antiplatelet that works by Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.. ACTRON is a NSAID that works by Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN and ACTRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is: 500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.. The standard adult dose of ACTRON is: Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN and ACTRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is classified as Category D/X. First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: A. ACTRON is classified as Category C. First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closur. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.